Business Context and Reporting Period
This Form 8-K is filed by AgeX Therapeutics, Inc. (trading symbol: AGE) for the reporting period ending June 2, 2023. The company is an emerging growth company incorporated in Delaware. The filing primarily addresses amendments to a secured convertible promissory note and a subsequent drawdown of funds.
Key Financial Metrics
- Debt Obligation: On June 7, 2023, the company drew $500,000 under its Secured Convertible Promissory Note with Juvenescence Limited.
- Repayment Date: The outstanding principal balance of the Secured Note is due and payable on February 14, 2024.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, or cash flow metrics.
- Liquidity: The amendment allows the company to draw on the available portion of the line of credit until the earlier of a Qualified Offering or October 31, 2023, subject to lender discretion.
Material Changes
On June 2, 2023, AgeX entered into a Third Amendment to its Secured Note with Juvenescence Limited. Key changes include:
- Drawdown Extension: AgeX may draw on the credit line until October 31, 2023, or until a Qualified Offering is consummated, whichever is earlier.
- Warrant Waiver: AgeX is no longer obligated to issue additional common stock purchase warrants to Juvenescence for loan funds received under the Second Amendment.
- Reverse Financing Condition: The deadline for fulfilling the condition permitting borrowing by Reverse Bioengineering, Inc. was extended to June 20, 2023.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the company's ability to consummate a Qualified Offering and its future borrowing capacity. Management notes that actual results may differ materially due to risk factors detailed in periodic SEC reports. The company disclaims any obligation to update these forward-looking statements. The immediate outlook is contingent on the company's ability to secure a Qualified Offering before the October 31, 2023 deadline to maintain access to the credit line.
Investor Verification Checklist
- Verify the total outstanding principal balance of the Secured Note following the $500,000 drawdown.
- Confirm the specific terms and conditions of the "Qualified Offering" required to extend the credit line beyond October 31, 2023.
- Review the full text of the Third Amendment (Exhibit 10.1) for any covenants or restrictions not summarized in this report.
- Check the company's most recent Form 10-Q (filed May 12, 2023) for a complete summary of the Secured Note's material terms.